
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIRACEPT | Agouron Pharmaceuticals | N-020779 RX | 1997-03-14 | 1 products, RLD, RS |
| VIRACEPT | Agouron Pharmaceuticals | N-021503 RX | 2003-04-30 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| viracept | New Drug Application | 2025-12-11 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | 4 | — | 1 | 6 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 1 | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Aids-associated nephropathy | D016263 | EFO_0007313 | — | — | — | 1 | — | — | 1 |
| Drug common name | Nelfinavir |
| INN | nelfinavir |
| Description | Nelfinavir is an aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. It has a role as a HIV protease inhibitor and an antineoplastic agent. It is a member of benzamides, a member of phenols, an aryl sulfide, a secondary alcohol, a tertiary amino compound and an organic heterobicyclic compound. It is a conjugate base of a nelfinavir(1+). |
| Classification | Small molecule |
| Drug class | antivirals: HIV protease inhibitors (saquinavir type) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C |
| PDB | — |
| CAS-ID | 159989-64-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL584 |
| ChEBI ID | 7496 |
| PubChem CID | 64143 |
| DrugBank | DB00220 |
| UNII ID | HO3OGH5D7I (ChemIDplus, GSRS) |






